Mutation prevalence tables for hereditary cancer derived from multigene panel testing

Steven N. Hart, Eric C. Polley, Amal Yussuf, Siddhartha Yadav, David E. Goldgar, Chunling Hu, Holly LaDuca, Laura P. Smith, June Fujimoto, Shuwei Li, Fergus J. Couch, Jill S. Dolinsky

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Multigene panel testing for cancer predisposition mutations is becoming routine in clinical care. However, the gene content of panels offered by testing laboratories vary significantly, and data on mutation detection rates by gene and by the panel is limited, causing confusion among clinicians on which test to order. Using results from 147,994 multigene panel tests conducted at Ambry Genetics, we built an interactive prevalence tool to explore how differences in ethnicity, age of onset, and personal and family history of different cancers affect the prevalence of pathogenic mutations in 31 cancer predisposition genes, across various clinically available hereditary cancer gene panels. Over 13,000 mutation carriers were identified in this high-risk population. Most were non-Hispanic white (74%, n = 109,537), but also Black (n = 10,875), Ashkenazi Jewish (n = 10,464), Hispanic (n = 10,028), and Asian (n = 7,090). The most prevalent cancer types were breast (50%), ovarian (6.6%), and colorectal (4.7%), which is expected based on genetic testing guidelines and clinician referral for testing. The Hereditary Cancer Multi-Gene Panel Prevalence Tool presented here can be used to provide insight into the prevalence of mutations on a per-gene and per-multigene panel basis, while conditioning on multiple custom phenotypic variables to include race and cancer type.

Original languageEnglish (US)
Pages (from-to)e1-e6
JournalHuman mutation
Issue number8
StatePublished - Aug 1 2020


  • BRCA1
  • BRCA2
  • cancer mutation prevalence
  • carrier
  • mutation risk

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)


Dive into the research topics of 'Mutation prevalence tables for hereditary cancer derived from multigene panel testing'. Together they form a unique fingerprint.

Cite this